Clinical momentum Palisade Bio is a clinical-stage biopharma with lead program PALI-2108 targeting inflammatory and fibrotic diseases, advancing from Phase 1 to planned Phase 2 trials for ulcerative colitis and Crohn’s disease, indicating opportunity for early-stage collaboration discussions and potential co-development or partnering on later-stage trials.

Targeted PDE4 The company’s differentiated orally administered PDE4 inhibitor prodrug aims to localize activation to the ileum and colon, offering a potentially safer and better-tolerated profile which could appeal to pharma, biotech, and contract research organizations seeking novel inflammatory bowel disease therapies.

Strategic partnerships Recent leadership and board expansions, plus active participation in industry events and advisory appointments, signal a readiness to engage with strategic partners, investors, and contract research partners to accelerate development, manufacturing, and commercialization discussions.

Clinical data signals Positive signals from Phase 1a and Phase 1b trials in UC and FSCD, along with scheduled Phase 2 studies, create opportunities for CROs, regulatory consultants, and KOL networks to offer services, trial design support, and patient recruitment partnerships.

Market outreach Active engagement in industry forums (Leerink Forum, NYAS, DDW) and a growing visibility in inflammatory and fibrotic disease spaces provide entry points for sponsored presentations, partnering conversations, and investigator-initiated study collaborations with gastroenterology researchers and clinics.